UBS Group
CNMD icon

UBS Group’s CONMED CNMD Stock Holding History

UBS Group’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.67M Buy
142,655
+25,722
+22% +$926K ﹤0.01% 4234
2026
Q1 		$4.13M Buy
116,933
+71,750
+159% +$2.92M ﹤0.01% 4271
2025
Q4 		$1.83M Sell
45,183
-92,078
-67% -$4.01M ﹤0.01% 5056
2025
Q3 		$6.46M Buy
137,261
+84,617
+161% +$4.39M ﹤0.01% 3776
2025
Q2 		$2.74M Sell
52,644
-37,530
-42% -$2.06M ﹤0.01% 4489
2025
Q1 		$5.45M Buy
90,174
+31,798
+54% +$2.05M ﹤0.01% 3699
2024
Q4 		$4M Buy
58,376
+41,397
+244% +$2.88M ﹤0.01% 4074
2024
Q3 		$1.22M Buy
16,979
+5,774
+52% +$407K ﹤0.01% 4477
2024
Q2 		$777K Sell
11,205
-45,654
-80% -$3.33M ﹤0.01% 4652
2024
Q1 		$4.55M Buy
56,859
+29,691
+109% +$2.65M ﹤0.01% 3076
2023
Q4 		$2.98M Buy
27,168
+10,837
+66% +$1.12M ﹤0.01% 3374
2023
Q3 		$1.65M Sell
16,331
-17,160
-51% -$1.97M ﹤0.01% 3632
2023
Q2 		$4.55M Sell
33,491
-14,088
-30% -$1.72M ﹤0.01% 2683
2023
Q1 		$4.94M Buy
47,579
+2,922
+7% +$283K ﹤0.01% 2532
2022
Q4 		$3.96M Sell
44,657
-1,949
-4% -$162K ﹤0.01% 2723
2022
Q3 		$3.74M Buy
46,606
+37,816
+430% +$3.57M ﹤0.01% 2617
2022
Q2 		$842K Sell
8,790
-33,224
-79% -$3.99M ﹤0.01% 3866
2022
Q1 		$6.24M Sell
42,014
-17,597
-30% -$2.46M ﹤0.01% 2329
2021
Q4 		$8.45M Buy
59,611
+58,068
+3,763% +$8.22M ﹤0.01% 2300
2021
Q3 		$202K Sell
1,543
-1,143
-43% -$150K ﹤0.01% 5305
2021
Q2 		$369K Sell
2,686
-12,708
-83% -$1.74M ﹤0.01% 4943
2021
Q1 		$2.01M Sell
15,394
-5,510
-26% -$663K ﹤0.01% 3567
2020
Q4 		$2.34M Buy
20,904
+5,196
+33% +$492K ﹤0.01% 3261
2020
Q3 		$1.24M Sell
15,708
-1,217
-7% -$99.3K ﹤0.01% 3490
2020
Q2 		$1.22M Sell
16,925
-4,532
-21% -$315K ﹤0.01% 3334
2020
Q1 		$1.23M Sell
21,457
-16,338
-43% -$1.51M ﹤0.01% 3179
2019
Q4 		$4.23M Buy
37,795
+13,383
+55% +$1.43M ﹤0.01% 2761
2019
Q3 		$2.35M Buy
24,412
+13,652
+127% +$1.28M ﹤0.01% 3139
2019
Q2 		$921K Buy
10,760
+8,601
+398% +$707K ﹤0.01% 3815
2019
Q1 		$179K Sell
2,159
-15,714
-88% -$1.14M ﹤0.01% 4678
2018
Q4 		$1.15M Buy
17,873
+1,191
+7% +$81.5K ﹤0.01% 3545
2018
Q3 		$1.32M Buy
16,682
+6,927
+71% +$536K ﹤0.01% 3587
2018
Q2 		$714K Buy
9,755
+8,111
+493% +$552K ﹤0.01% 4047
2018
Q1 		$104K Sell
1,644
-1,889
-53% -$113K ﹤0.01% 5192
2017
Q4 		$180K Buy
3,533
+335
+10% +$17.4K ﹤0.01% 4992
2017
Q3 		$168K Buy
3,198
+2,963
+1,261% +$149K ﹤0.01% 4965
2017
Q2 		$12K Sell
235
-65
-22% -$3.22K ﹤0.01% 6637
2017
Q1 		$13K Sell
300
-4,286
-93% -$184K ﹤0.01% 6441
2016
Q4 		$202K Buy
4,586
+4,043
+745% +$172K ﹤0.01% 4778
2016
Q3 		$22K Sell
543
-2,846
-84% -$121K ﹤0.01% 6216
2016
Q2 		$162K Buy
3,389
+1,600
+89% +$67.7K ﹤0.01% 4681
2016
Q1 		$76K Sell
1,789
-15
-0.8% -$589 ﹤0.01% 5173
2015
Q4 		$79K Buy
1,804
+121
+7% +$5.25K ﹤0.01% 5400
2015
Q3 		$80K Buy
1,683
+917
+120% +$50.3K ﹤0.01% 5404
2015
Q2 		$44K Sell
766
-443
-37% -$23.9K ﹤0.01% 6104
2015
Q1 		$61K Sell
1,209
-11,235
-90% -$551K ﹤0.01% 5860
2014
Q4 		$560K Buy
+12,444
New +$522K ﹤0.01% 4095

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

UBS Group's CNMD Position: Q2 2026 in Review

UBS Group increased its CONMED (CNMD) stake by 22% in Q2 2026, buying an estimated $926K and bringing the position to 142,655 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #4234.

UBS Group first reported a position in CNMD in Q4 2014 and has held it in 47 quarters since. The position peaked at $8.45M in Q4 2021. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • UBS Group held 142,655 shares of CONMED worth $4.67M as of Q2 2026.
  • UBS Group bought 25,722 CONMED shares in Q2 2026, an estimated $926K.
  • CONMED made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4234 holding.
  • UBS Group first reported a position in CONMED in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's CONMED position peaked at $8.45M in Q4 2021.
  • 246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.